SG10202010291VA - Dihydropyrimidin-2-one compounds and medical use thereof - Google Patents

Dihydropyrimidin-2-one compounds and medical use thereof

Info

Publication number
SG10202010291VA
SG10202010291VA SG10202010291VA SG10202010291VA SG10202010291VA SG 10202010291V A SG10202010291V A SG 10202010291VA SG 10202010291V A SG10202010291V A SG 10202010291VA SG 10202010291V A SG10202010291V A SG 10202010291VA SG 10202010291V A SG10202010291V A SG 10202010291VA
Authority
SG
Singapore
Prior art keywords
dihydropyrimidin
compounds
medical use
medical
Prior art date
Application number
SG10202010291VA
Inventor
Masahiro Yokota
Taku Ikenogami
Eiichi Watanabe
Noriyoshi Seki
Takayuki Sakai
Shingo Fujioka
Makoto Shiozaki
Katsunori Suwa
Yosuke Ogoshi
Masato Noguchi
Katsuya Maeda
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of SG10202010291VA publication Critical patent/SG10202010291VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C265/00—Derivatives of isocyanic acid
    • C07C265/02—Derivatives of isocyanic acid having isocyanate groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/12—Organo silicon halides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
SG10202010291VA 2014-12-12 2015-12-11 Dihydropyrimidin-2-one compounds and medical use thereof SG10202010291VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014251771 2014-12-12

Publications (1)

Publication Number Publication Date
SG10202010291VA true SG10202010291VA (en) 2020-11-27

Family

ID=56107519

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201703885TA SG11201703885TA (en) 2014-12-12 2015-12-11 Dihydropyrimidin-2-one compounds and medical use thereof
SG10202010291VA SG10202010291VA (en) 2014-12-12 2015-12-11 Dihydropyrimidin-2-one compounds and medical use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201703885TA SG11201703885TA (en) 2014-12-12 2015-12-11 Dihydropyrimidin-2-one compounds and medical use thereof

Country Status (33)

Country Link
US (4) US10196363B2 (en)
EP (2) EP3744713A1 (en)
JP (4) JP6757565B2 (en)
KR (1) KR102551018B1 (en)
CN (1) CN107001286B (en)
AR (1) AR102972A1 (en)
AU (1) AU2015362394C1 (en)
BR (1) BR112017010471B1 (en)
CA (1) CA2965804C (en)
CL (1) CL2017001467A1 (en)
CO (1) CO2017005732A2 (en)
CY (1) CY1122971T1 (en)
DK (1) DK3231793T3 (en)
ES (1) ES2787700T3 (en)
HR (1) HRP20200584T1 (en)
HU (1) HUE048503T2 (en)
IL (2) IL251940B (en)
LT (1) LT3231793T (en)
ME (1) ME03760B (en)
MX (1) MX371128B (en)
MY (1) MY193671A (en)
PE (1) PE20171119A1 (en)
PH (1) PH12017501071A1 (en)
PL (1) PL3231793T3 (en)
PT (1) PT3231793T (en)
RS (1) RS60352B1 (en)
RU (1) RU2770061C2 (en)
SA (1) SA517381678B1 (en)
SG (2) SG11201703885TA (en)
SI (1) SI3231793T1 (en)
TW (2) TWI739206B (en)
WO (1) WO2016093342A1 (en)
ZA (1) ZA201703976B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI739206B (en) * 2014-12-12 2021-09-11 日商日本煙草產業股份有限公司 Dihydropyrimidin-2-one compound and pharmaceutical use thereof
CN106496008A (en) * 2016-10-20 2017-03-15 上海毕得医药科技有限公司 A kind of method of synthesis 4 (4 chlorphenyl) cyclohexanone
MX2020008929A (en) * 2018-02-28 2020-10-01 Japan Tobacco Inc Saturated ring-condensed dihydropyrimidinone or dihydrotriazinone compound, and pharmaceutical use thereof.
KR20200126973A (en) 2018-02-28 2020-11-09 니뽄 다바코 산교 가부시키가이샤 4-methyldihydropyrimidinone compound and its pharmaceutical use
CN110294762B (en) * 2019-06-14 2020-12-15 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） Artificial antigen for detecting acidosis of rice fermentum and application thereof
WO2021149786A1 (en) 2020-01-24 2021-07-29 Japan Tobacco Inc. Methods of treating cancer using dihydropyrimidin-2-one compounds
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485107A (en) * 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
EP1962855B1 (en) * 2005-12-22 2013-08-21 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
DE102006031314A1 (en) * 2006-07-01 2008-01-03 Bayer Healthcare Aktiengesellschaft Use of 1,4-diaryl-dihydropyrimidin-2-one derivative for producing a medicament for the treatment and/or prophylaxis of e.g. pulmonary arterial hypertension, chronic-obstructive lung diseases and sleep apnea syndrome
MX2010001195A (en) 2007-08-09 2010-03-01 Hoffmann La Roche Benzoyl-piperidine derivatives as dual modulators of the 5-ht2a and d3 receptors.
WO2009150668A1 (en) * 2008-06-13 2009-12-17 Delhi University Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same
BR112013027670B1 (en) 2011-04-28 2021-11-09 Japan Tobacco Inc AMIDA COMPOUND, PHARMACEUTICAL COMPOSITION AND DRUG COMPRISING HIM AND RORY'S ANTAGONIST
EP2682389A1 (en) 2012-07-02 2014-01-08 Commissariat A L'energie Atomique Et Aux Energies Alternatives Dihydropyrimidin-2(1H)-ones and dihydropyrimidin-2(1H)-thiones as inhibitors of sodium iodide symporter
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
US20160137639A1 (en) * 2012-10-26 2016-05-19 Japan Tobacco Inc. Triazole-isoxazole compound and medical use thereof
CN103113308B (en) * 2013-01-25 2014-11-19 浙江大学 Method for preparing dihydropyrimidinone derivative
MA41148A (en) 2014-12-12 2017-10-17 H Lundbeck As IDALOPIRDINE MANUFACTURING PROCESS
TWI739206B (en) * 2014-12-12 2021-09-11 日商日本煙草產業股份有限公司 Dihydropyrimidin-2-one compound and pharmaceutical use thereof
KR20170095964A (en) 2014-12-12 2017-08-23 에이스틸론 파마수티컬스 인코포레이티드 Piperidine derivatives as hdac1/2 inhibitors
KR20170090499A (en) 2014-12-12 2017-08-07 메르크 파텐트 게엠베하 Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor
SG11201704523WA (en) 2014-12-12 2017-07-28 H Lundbeck As A process for the manufacture of idalopirdine

Also Published As

Publication number Publication date
BR112017010471A2 (en) 2017-12-26
JP6757565B2 (en) 2020-09-23
CL2017001467A1 (en) 2018-01-05
US20230373932A1 (en) 2023-11-23
HRP20200584T1 (en) 2020-07-10
CA2965804A1 (en) 2016-06-16
PH12017501071A1 (en) 2017-12-18
EP3744713A1 (en) 2020-12-02
SA517381678B1 (en) 2021-12-14
DK3231793T3 (en) 2020-05-11
RU2017124423A (en) 2019-01-15
CA2965804C (en) 2023-10-10
IL251940A0 (en) 2017-06-29
EP3231793A1 (en) 2017-10-18
US20190359575A1 (en) 2019-11-28
LT3231793T (en) 2020-04-27
WO2016093342A1 (en) 2016-06-16
HUE048503T2 (en) 2020-07-28
AR102972A1 (en) 2017-04-05
ES2787700T3 (en) 2020-10-16
AU2015362394A1 (en) 2017-05-25
PE20171119A1 (en) 2017-08-08
EP3231793B1 (en) 2020-03-11
JP2024133646A (en) 2024-10-02
AU2015362394C1 (en) 2021-01-28
RU2770061C2 (en) 2022-04-14
TWI739206B (en) 2021-09-11
RS60352B1 (en) 2020-07-31
CO2017005732A2 (en) 2017-08-31
MX2017007577A (en) 2017-09-28
PL3231793T3 (en) 2020-07-27
IL283335B (en) 2022-04-01
MY193671A (en) 2022-10-24
ME03760B (en) 2021-04-20
AU2015362394B2 (en) 2020-07-02
IL283335A (en) 2021-07-29
BR112017010471B1 (en) 2024-02-27
TWI690515B (en) 2020-04-11
PT3231793T (en) 2020-05-06
JP2022116239A (en) 2022-08-09
US20160194290A1 (en) 2016-07-07
TW202012377A (en) 2020-04-01
ZA201703976B (en) 2019-06-26
JP2020200339A (en) 2020-12-17
RU2017124423A3 (en) 2019-08-13
US20210130300A1 (en) 2021-05-06
CN107001286B (en) 2020-07-07
CY1122971T1 (en) 2021-10-29
SI3231793T1 (en) 2020-07-31
US10196363B2 (en) 2019-02-05
KR20170090497A (en) 2017-08-07
KR102551018B1 (en) 2023-07-05
IL251940B (en) 2021-06-30
CN107001286A (en) 2017-08-01
EP3231793A4 (en) 2018-09-19
JP2016113455A (en) 2016-06-23
TW201639820A (en) 2016-11-16
MX371128B (en) 2020-01-17
NZ731607A (en) 2024-03-22
SG11201703885TA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
HK1243073A1 (en) Therapeutic compounds and uses thereof
HK1244000B (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
IL247072A0 (en) Medical use
GB201403093D0 (en) Therapeutic compounds and their use
IL283335B (en) Dihydropyrimidin-2-one compounds and medical use thereof
EP3020328C0 (en) Skin-mountable medical device
ZA201801134B (en) Hydroxytriazine compound and medical use thereof
IL250729A0 (en) Pyrazolothiazole compound and medicine comprising same
GB201403032D0 (en) Medical device
PT3129398T (en) New medical agents and uses thereof
GB201420805D0 (en) Ligatures and use thereof
PL3229772T3 (en) 6-aryl-9-glycosylpurines and use thereof
GB201410387D0 (en) Compounds and their therapeutic use
GB201514770D0 (en) Compounds and their use
GB201403496D0 (en) Compounds and their therapeutic use
GB201416899D0 (en) Medical devices and related methods
GB201413411D0 (en) Novel compounds and their use
GB201417777D0 (en) Novel compounds and therapeutic uses thereof
GB201410147D0 (en) Medical device